Analysis of tumor specimens obtained before and after CAR-T cell therapy (but before tebotelimab treatment) demonstrated a dynamic immune activation in the TME after CAR-T cell therapy, as evidenced by increased TILs and upregulation of LAG-3 and PD-1 (Extended Data Fig. 6f). Here, PDCD1 is linked to neoplasm.